Literature DB >> 8612380

Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population.

P M Mrozikiewicz1, I Cascorbi, J Brockmöller, I Roots.   

Abstract

The frequency of various genotypes of arylamine N-acetyltransferase (NAT2) was investigated in 248 Polish unrelated children. Allele-specific polymerase chain reaction (PCR) was applied for mutation at 341 nucleotide (nt) of NAT2 coding sequence and PCR/restriction fragment length polymorphism for the other mutations. Genotypes coded for slow acetylation in 62.9% (56.6% to 68.9%). The frequency of specific NAT2 alleles was *4 (wild-type), 22.0%; *5A (341C, 481T), 5.2%; *5B (341C, 481T, 803G), 33.1%; *5C (341C, 803G), 6.0%; *6A (282T, 590A), 30.0%; *7B (282T, 857A), 3.4%; and *12A (803G), 0.2%. No mutations were found at 191, 434, and 845 nt. By a molecular-genetic procedure, genotypes *4/*6A were confirmed not to mask *6B/*13 (590A/282T). *6B and *13 were absent in a composite sample representative of 826 alleles (95% confidence limits, 0% to 0.45%). Five cases of genotype-phenotype discrepancy were sequenced and their mutation allocation confirmed; 21 further genotypes were confirmed by sequencing. This first evaluation of NAT2 genes among a Slavic population should provide a basis for clinical and epidemiologic investigations of NAT2 in the Polish population.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612380     DOI: 10.1016/S0009-9236(96)90104-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

Authors:  Elena A Gaikovitch; Ingolf Cascorbi; Przemyslaw M Mrozikiewicz; Jürgen Brockmöller; Roland Frötschl; Karla Köpke; Thomas Gerloff; Jury N Chernov; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2003-07-15       Impact factor: 2.953

2.  Association between the N-acetylation genetic polymorphism and bronchial asthma.

Authors:  Muradiye Nacak; A Sükrü Aynacioglu; Ayten Filiz; Ingolf Cascorbi; M Emin Erdal; Necat Yilmaz; Erhan Ekinci; Ivar Roots
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

3.  Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.

Authors:  R Salazar-González; R Gómez; S Romano-Moreno; S Medellín-Garibay; A Núñez-Ruíz; M Magaña-Aquino; R C Milán-Segovia; D P Portales-Pérez
Journal:  Mol Biol Rep       Date:  2014-08-28       Impact factor: 2.316

4.  Inferring haplotypes at the NAT2 locus: the computational approach.

Authors:  Audrey Sabbagh; Pierre Darlu
Journal:  BMC Genet       Date:  2005-06-02       Impact factor: 2.797

5.  Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history.

Authors:  Audrey Sabbagh; André Langaney; Pierre Darlu; Nathalie Gérard; Rajagopal Krishnamoorthy; Estella S Poloni
Journal:  BMC Genet       Date:  2008-02-27       Impact factor: 2.797

6.  Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

Authors:  E Zielińska; W Niewiarowski; J Bodalski; G Rebowski; J Skretkowicz; K Mianowska; M Sekulska
Journal:  Pharm World Sci       Date:  1998-06

7.  NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.

Authors:  Recep Dursun; Hatice Gül Dursun; Ayşe Gül Zamani; Mahmut Selman Yıldırım; İlknur Çınar
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.